Stay updated on ABP 215 vs Bevacizumab in Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the ABP 215 vs Bevacizumab in Advanced NSCLC Clinical Trial page.

Latest updates to the ABP 215 vs Bevacizumab in Advanced NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section updated to include North Dakota, Western Australia, and Veliko Tarnovo (revision 3.3.3). HHS Vulnerability Disclosure and related location entries (North Dakota, Western Australia, Veliko Tarnovo) were removed (revision 3.3.2).SummaryDifference0.4%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedFooter revision tag updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedPublications section wording was updated to indicate items are automatically filled from PubMed, and the revision tag was updated to v3.3.1.SummaryDifference0.1%

- Check49 days agoChange DetectedNotice about government funding lapse and NIH/CC operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedNo additions or deletions detected on the page; the study details and eligibility criteria appear unchanged.SummaryDifference0.4%

- Check92 days agoChange DetectedUpdated operating status notice and version to v3.2.0; removes previous v3.1.0 reference and directs users to current status sources.SummaryDifference3%

Stay in the know with updates to ABP 215 vs Bevacizumab in Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 215 vs Bevacizumab in Advanced NSCLC Clinical Trial page.